Articles related to Neuromusculoskeletal Medicine & OMM

Healthcare professionals should be aware of the potential for neurological side effects in patients receiving COVID-19 vaccines. With nearly one-third of vaccine recipients experiencing symptoms such as headaches, tremors, and insomnia, continued monitoring and research are crucial.

The approval of Combogesic IV, backed by data from two phase 3 studies, signifies a major breakthrough in our ongoing efforts to provide effective and safer alternatives to opioids for postoperative pain management.

Discover how AOC 1044’s recent FDA orphan drug designation could revolutionize the treatment landscape for Duchenne muscular dystrophy patients with exon 44 mutations. Stay tuned for upcoming results from the EXPLORE44 trial.

The recent phase 3 trial of vorasidenib in patients with grade 2 IDH-mutant glioma has demonstrated significant improvements in progression-free survival and time to next intervention. Explore the detailed findings to understand how this oral inhibitor could become a vital part of the treatment regimen for this challenging condition.

Explore the study’s analysis, which also uncovers potential cardiovascular benefits associated with SGLT2i initiation among patients with gout and type 2 diabetes.

Explore the multidisciplinary approach to bone metastasis management, emphasizing early detection, proactive intervention, and the significant role of primary care providers in this process.